Dihydroresveratrol

Dihydroresveratrol is a reduced form of resveratrol that demonstrates enhanced bioavailability and stability compared to its parent compound. It activates AMPK and SIRT1 pathways to support cellular energy metabolism and insulin sensitivity.

Origin & History

Dihydroresveratrol (DHR) is a natural dihydrostilbenoid and a primary active metabolite of resveratrol, found in sources like wine and certain plants. For research purposes, it is typically produced via the catalytic hydrogenation of trans-resveratrol. It is classified as a stilbenol and is a focus of modern preclinical study.

Historical & Cultural Context

No historical or traditional medicinal uses for dihydroresveratrol are documented in the provided research. It is primarily known as a modern research compound and a metabolite of resveratrol, rather than an ingredient with a history of traditional use.[1][2]

Health Benefits

["\u2022 May support cellular energy balance by activating the AMP-activated protein kinase (AMPK) signaling pathway (preclinical evidence).[1]", "\u2022 May promote insulin sensitivity through the activation of downstream targets like SIRT1 (preclinical evidence).[1]", "\u2022 May inhibit adipogenesis (the formation of fat cells) via the AMPK pathway (preclinical evidence).[1]", "\u2022 May exert anti-inflammatory effects by inhibiting the NLRP3 inflammasome and reducing pro-inflammatory cytokines like IL-1\u03b2 and IL-6 (preclinical evidence).[1]", "\u2022 May modulate cellular responses by activating the aryl hydrocarbon receptor (AHR) and inhibiting p38 MAPK (preclinical evidence).[1]"]

How It Works

Dihydroresveratrol activates AMP-activated protein kinase (AMPK) signaling pathways, which regulate cellular energy homeostasis. It also stimulates sirtuin 1 (SIRT1) deacetylase activity, promoting mitochondrial biogenesis and glucose metabolism. The compound inhibits adipogenesis through modulation of PPAR-gamma and C/EBP transcription factors.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses specifically investigating dihydroresveratrol were identified in the available research. All current evidence is derived from preclinical in vitro and animal models, and therefore no PMIDs for human studies are available.[1][2]

Clinical Summary

Research on dihydroresveratrol is primarily limited to preclinical studies and cell culture models. Animal studies have shown improved glucose tolerance and reduced adipose tissue formation, but specific dosages and duration vary widely across studies. No large-scale human clinical trials have been conducted to establish therapeutic efficacy. The evidence base remains preliminary compared to its parent compound resveratrol.

Nutritional Profile

Dihydroresveratrol (DHR) is a pure bioactive polyphenolic compound, not a whole food, and therefore does not contain macronutrients, vitamins, minerals, or fiber in the traditional nutritional sense. As a single molecule (C14H14O3, molecular weight ~230.26 g/mol), its profile is defined entirely by its chemical identity and bioavailability characteristics. It is a reduced metabolite of resveratrol, differing by the saturation of the 4,5-double bond in the stilbene backbone. Structurally, it retains two phenolic hydroxyl groups and one methoxy group, which contribute to its antioxidant and signaling properties. Typical research and supplement doses range from 10–100 mg per administration in preclinical models; human dosing is not yet standardized. Bioavailability: DHR demonstrates notably improved oral bioavailability compared to its parent compound resveratrol, primarily because the saturated double bond renders it more resistant to rapid phase II metabolism (glucuronidation and sulfation) in the gut and liver. Studies suggest DHR achieves higher plasma concentrations and longer half-life than resveratrol at equivalent doses. It is lipophilic in nature (logP estimated ~2.5–3.0), meaning absorption is enhanced when taken with dietary fat. It is found endogenously as a gut microbiota-derived metabolite of resveratrol. No caloric value, protein, carbohydrate, fat, or micronutrient content is applicable to this compound in isolation.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details for dihydroresveratrol have been established, as human trials are lacking. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Resveratrol, Quercetin, Berberine, Curcumin, EGCG (from Green Tea)

Safety & Interactions

Safety data for dihydroresveratrol in humans is limited due to the lack of clinical trials. Based on its structural similarity to resveratrol, potential interactions with anticoagulant medications and blood sugar-lowering drugs may occur. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data. Individuals with hormone-sensitive conditions should exercise caution as stilbenes may have estrogenic effects.